Narrowband (311-nm) UV-B Therapy for Small Plaque Parapsoriasis and Early-Stage Mycosis Fungoides

Angelika Hofer, MD; Lorenzo Cerroni, MD; Helmut Kerl, MD; Peter Wolf, MD

**Background:** Broadband UV-B phototherapy has been used for many years in the treatment of small plaque parapsoriasis (SPP) and early-stage mycosis fungoides (MF). Our purpose was to investigate the effect on these diseases of narrowband (311-nm) UV-B therapy, which was recently established for the treatment of psoriasis and found to be more effective than broadband UV-B therapy.

**Observations:** Twenty patients (5 women, 15 men; age range, 39-85 years) with histologically confirmed SPP or early-stage MF were enrolled. Six patients had early-stage MF (patch stage), and 14 had SPP. Treatment with 311-nm UV-B was given 3 to 4 times a week for 5 to 10 weeks. In 19 patients, lesions completely cleared after a mean number of 20 treatments (range, 14-29 treatments) and a mean cumulative UV-B dose of 16.3 J/cm² (range, 7.4-36.4 J/cm²) within a mean time of 6 weeks (range, 5-10 weeks). Biopsy specimens taken immediately after the end of phototherapy showed only sparse inflammatory infiltrates but no signs of SPP or MF. Relapses at cutaneous sites occurred in all patients within a mean time of 6 months (range, 2-15 months).

**Conclusions:** Narrowband UV-B therapy is an effective short-term treatment modality for clearing SPP and early-stage MF. However, the treatment response did not sustain long-term remission. Further studies are necessary to examine how the clinical response to and follow-up after narrowband UV-B therapy compares with that of established phototherapy modalities in these diseases.

Arch Dermatol. 1999;135:1377-1380

---

TREATMENT OF small and large plaque parapsoriasis and mycosis fungoides (MF) for many years has consisted of UV-B¹ as well as psoralen–UV-A (PUVA)²-⁶ therapy. Although large plaque parapsoriasis is considered an early form of MF, the relation of small plaque parapsoriasis (SPP) to MF is still a matter of discussion.⁷-⁹ However, to prevent early-stage MF from progressing, an early aggressive therapy and careful monitoring of the patients may be necessary.¹⁰

Narrowband UV-B was introduced recently for the treatment of psoriasis and found to be more effective than broadband UV-B at clearing psoriatic lesions.¹¹ Indeed, even when compared with PUVA phototherapies, narrowband UV-B was reported to have on average the same efficacy but fewer side effects.¹² Therefore, the purpose of our study was to investigate the effect of narrowband (311-nm) UV-B in patients with SPP and early-stage MF.

All 20 patients completed the study, and 19 (95%) had a complete clinical remission (patients with SPP, 14 of 14; patients with MF, 5 of 6) (Table 1 and Figure 1). Complete clearance of skin lesions in those 19 patients was observed after a mean number of 20 treatments (range, 14-29 treatments) and a mean cumulative UV-B dose of 16.3 J/cm² (range, 7.4-36.4 J/cm²) within a mean time of 44 days (range, 36-69 days). The clinical remission could be confirmed histologically in 13 patients who agreed to have a punch biopsy specimen taken before and after therapy (Figure 2). The posttreatment biopsy specimens of these patients showed only a sparse inflammatory infiltrate but no features typical of SPP or MF (Figure 2, right). One patient with MF (patient 16) showed only a partial response to 311-nm UV-B but a complete clinical response to PUVA therapy. In 5 (26%) of 19 patients who had a complete clinical response, postinflammatory hyperpigmentation occurred at the site of diseased skin.

In the follow-up period, relapses occurred in all patients within a mean time of 6 months (range, 2-15 months) (Table and Figure 3). There was no statistically significant difference in the primary response rate (Fisher exact test, P = .30) or in the response rate on long-term follow-up (log-

---

©1999 American Medical Association. All rights reserved.
rank test, \( P = .73 \)) between patients with SPP and those with early-stage MF (patch stage) (Figure 3). In 7 (37%) of 19 patients who had complete clearance, the skin changes associated with relapse were less widespread and intense, and topical steroids were then effective at producing clearance again. Five patients (patients 1, 2, 12, 13, and 18) were again treated with 311-nm UV-B and again responded with complete clearing (data not shown).

**Determination of Clinical Response**

Clinical response was rated as follows: complete response, more than 93% clearing of skin lesions; partial response, 50% to 93%; and no response, less than 50%. Before and after therapy, 4-mm punch biopsy specimens were taken from each patient at the site of a representative skin lesion for histologic examination. The specimens were processed routinely and stained with hematoxylin-eosin for light microscopic examination.
To our knowledge, this is the first study showing that narrowband UV-B therapy is effective in clearing skin lesions of SPP and early-stage MF. Treatment with 311-nm UV-B cleared the skin lesions in 100% of patients with SPP and all but 1 patient with early-stage MF (Figure 1) within a mean time of 6 weeks. However, in the follow-up period, relapses occurred in all patients within a mean time of 6 months. One possible reason why relapse occurred so relatively quickly in all cases of SPP and early-stage MF treated with 311-nm UV-B may have been the lack of maintenance therapy and/or slow tapering schedule after remission.

Compared with broadband UV-B therapy, 311-nm UV-B therapy as applied herein seemed to induce an equal or even higher primary response rate in patients with SPP as well as those with early-stage MF.1,15 For instance, Ramsay et al1 showed in a retrospective nonrandomized study of 37 patients with early (stages IA-IIB) cutaneous T-cell lymphoma (CTCL) that broadband UV-B treatment produced complete clearance in 25 (83%) of 30 patients with stage I CTCL after a median time of 5 months, but produced no response in any patients with stage II CTCL. Among the patients who achieved complete remission, 5 (20%) had a relapse after a median time of 5 months (range, 1-33 months); in 2 of these patients, relapse occurred during UV-B maintenance therapy, which was given to all patients for at least 3 months. Resnik and Vonderheid15 reported on the long-term follow-up of 31 patients with early MF of stage IA (21 patients), stage IB (9 patients), and stage IIA (1 patient) treated with commercially available home UV phototherapy units emitting UV radiation in the UV-A and UV-B wavelength range (280-350 nm). Twenty-three (74%) of 31 patients achieved a complete clinical response after a mean time of 5 months (range, 1-38 months), but 12 (63%) of 19 patients available for follow-up suffered relapses after a median of 16.5 months (range, 3-109 months). Compared with our 311-nm UV-B treatment, the
home phototherapy regimen was much more time-consuming and produced a much lower clearance rate.

However, our results compare well with the primary response rates reported for PUVA treatment of parapsoriasis en plaques and early-stage MF. For instance, Rosenbaum et al. reported an overall initial complete response rate of 58% (25 of 43 patients) with CTCL, including parapsoriasis en plaques (7 patients) and plaque-stage (23 patients), tumor-stage (5 patients), and erythrodermic MF (8 patients). Although maintenance PUVA treatment was given in 17 (68%) of 25 patients, the disease recurred after a mean of approximately 6 months. Herrmann et al. observed complete clinical and histologic clearing in 53 (69%) of 82 patients with MF of all stages (including 68 patients [83%] with stage 1A or 1B ) with a mean duration of total complete response of 43 months.

Until now there have been only a few, mostly retrospective studies concerning the treatment of SPP and MF with UV-B therapy or PUVA phototherapy. Therefore, prospective, randomized studies seem to be desirable for comparing the clinical efficacy of PUVA, broadband UV-B, and 311-nm UV-B in the treatment of SPP and early-stage MF. Those studies should show whether 311-nm UV-B therapy can gain a place in the routine phototherapeutic armamentarium for early-stage CTCL.

Accepted for publication May 21, 1999.

Corresponding author: Peter Wolf, MD, Department of Dermatology, University of Graz, Auenbruggerplatz 8, A-8036, Graz, Austria (e-mail: peter.wolf@kfunigraz.ac.at).

REFERENCES

8. Ackerman AB. If small plaque (digitate) parapsoriasis is a cutaneous T-cell lymphoma, even an “abortive” one, it must be mycosis fungoides! Arch Dermatol. 1996;132:562-566.